Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04494700- Low Dose Arm · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Low Dose Arm | EXPERIMENTAL | - |
| High Dose Arm | EXPERIMENTAL | - |
| Placebo Control | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04494700 - Low Dose Arm | DRUG | 30 mg loading dose for 6 days, followed by 10 mg daily |
| PF-04494700 - High Dose Arm | DRUG | 60 mg loading dose for 6 days, followed by 20 mg daily |
| Placebo Comparator | DRUG | Matching placebo. |
Inclusion Criteria: * Diagnosis of probably Alzheimer's disease for at least 1 year. * Mini Mental State Exam (MMSE) score between 12-26 at screening. * Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months. Exc...
Top 20 of 24 competitors
PF-04494700 is an investigational small molecule being studied for Alzheimer's Disease and Diabetic Nephropathy. It has been evaluated in Phase 2 clinical trials for these conditions, including mild to moderate Alzheimer's Disease. The drug is not approved and remains in clinical development.
PF-04494700 is being developed by Pfizer, Inc., which trades under the ticker PFE. The company has conducted Phase 2 clinical trials of the drug for Alzheimer's Disease and Diabetic Nephropathy.
PF-04494700 is in Phase 2 clinical development. It has completed Phase 2 trials for Alzheimer's Disease and Diabetic Nephropathy. The drug is investigational and has not been approved by regulatory authorities.
PF-04494700 has completed three Phase 2 trials: NCT00141661, a safety and tolerability study in Alzheimer's patients; NCT00287183, a 6-month study in type 2 diabetes with albuminuria; and NCT00566397, an efficacy and safety study in mild to moderate Alzheimer's Disease.
PF-04494700 is also known as TTP488. In clinical trial NCT00287183, the drug is referred to as TTP488, indicating that these names refer to the same investigational compound being developed by Pfizer.